Evaluation of drug treatment in irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The irritable bowel syndrome (IBS) remains a therapeutic challenge in part because of the limited understanding of the pathophysiology. The placebo response rate varies in randomized controlled trials from 20 to 70%, and can persist for up to at least 1 year. It is contentious whether dietary fibre and bulking agents relieve the symptoms of IBS; constipation probably improves. Anticholinergic and antispasmodic agents are of questionable benefit in IBS despite positive meta‐analyses of poor quality trials. A meta‐analysis concluded that the tricyclic antidepressants were superior to placebo in IBS, although the individual trial results were variable. Selective serotonin reuptake inhibitors are of uncertain benefit. Laxatives are used for constipation but probably poorly control the IBS symptom complex. Loperamide is superior to placebo in improvement of diarrhoea but not abdominal pain in IBS. Tegaserod is a well‐ tolerated aminoguanidine indole derivative of serotonin that is a partial 5HT 4–receptor agonist with prokinetic properties; a therapeutic gain over placebo of 5% to 15% has been observed in constipation‐predominant IBS in females. Alosetron is a 5HT 3‐receptor antagonist that is efficacious in females with diarrhoea‐predominant IBS, with a 12% to 17% therapeutic gain; the risk of ischaemic colitis is 1 in 350, with very severe constipation occurring in about 1 in 1000. Optimizing study design remains a challenge in IBS. New visceral analgesic and motility modifying agents, as well as anti‐inflammatory agents are in trials, and hopefully additional efficacious therapeutic options for patients with IBS will soon emerge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Self-citationAGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
The role of psychological and biological factors in postinfective gut dysfunction
Gwee, K.-A., Leong, Y.-L., Graham, C., McKendrick, M. W., Collins, S. M., Walters, S. J., Underwood, J. E., & Read, N. W. (1999) · Gut · doi:10.1136/gut.44.3.400 · Cited by 764
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
Kellow, J. E., & Phillips, S. F. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90620-2 · Cited by 464
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443
The Irritable Bowel Syndrome: Long-Term Prognosis and the Physician-Patient Interaction
Owens, D. M., Nelson, D. K., & Talley, N. J. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00005 · Cited by 349
Self-citationEffect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236
GORARD, D. A., LIBBY, G. W., & FARTHING, M. J. G. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00273.x · Cited by 211
Cited by
(2011) · SpringerReference · doi:10.1007/springerreference_44317 · Cited by 545
Müller, A., Franke, H., Resch, K.-L., & Fryer, G. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.098 · Cited by 88
Use of psychopharmacological agents for functional gastrointestinal disorders.
Clouse, R. E., & Lustman, P. J. (2005) · Gut · doi:10.1136/gut.2004.048884 · Cited by 76
Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome
Gaman, A., Bucur, M. C., & Kuo, B. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08103656 · Cited by 12
“A potential limitation with the use of CCK antagonists could be induction of gallbladder stasis and possible cholelithiasis [Talley, 2003].”
Background
Metadata
- Authors
- Talley, N. J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-09-12
- Volume
- 56
- Issue
- 4
- Pages
- 362-369
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1566813966
- Cited by
- 78
- References
- 11
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of drug treatment in irritable bowel syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2125.2003.01966.x
- The paper
- Talley, N. J. (2003). Evaluation of drug treatment in irritable bowel syndrome. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2003.01966.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.